UK CRISPR Market (2025-2030)
The UK CRISPR Market was valued at $160.7 Million in 2025 and projected to reach to $284.7 Million by 2030, representing a compound annual growth rate of 12.1%. The UK CRISPR market is poised for sustained expansion through 2030, driven by increasing clinical trial activity, growing adoption in rare genetic disease treatment, and strengthening partnerships between academic institutions and commercial entities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK CRISPR Market Trends and Insights
- Valued at $160.7 million in 2025, the UK market is expected to expand to $284.7 million by 2030, reflecting a compound annual growth rate of 12.1%.
- This expansion is driven by the UK's robust regulatory framework, substantial investment in precision medicine, and a thriving biotech ecosystem centered in regions like Cambridge and London.
- The UK's commitment to advancing genomic medicine and its leadership in clinical trials has accelerated adoption of CRISPR-based therapeutics across oncology, rare genetic disorders, and immunotherapy applications. The UK market benefits from strong government support, including funding from the UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR).
- The UK's National Health Service (NHS) integration of gene therapies and its emphasis on personalized medicine create favorable conditions for CRISPR technology deployment.
- By 2030, the UK is anticipated to maintain its competitive edge through continued innovation, strategic partnerships with academic institutions, and regulatory clarity that attracts both domestic and international biotech investments..
Key Market Statistics
- CAGR (2025-2030) 12.1% CAGR
- Market Size, 2025 ~USD 160.7 Million
- Forecast, 2030 ~USD 284.7 Million
- Country UK
UK CRISPR Market Overview
Market Valuation & Growth :
The UK CRISPR market is valued at $160.7 million in 2025 and is projected to reach $284.7 million by 2030, representing a robust 12.1% CAGR, outpacing the global average of 11.2%.
Regulatory Leadership :
The UK benefits from a progressive and well-established regulatory framework that accelerates CRISPR-based therapeutic approvals, positioning it as a preferred hub for gene-editing innovation in Europe.
Biotech Ecosystem Strength :
The UK hosts a thriving biotech sector with significant concentration of CRISPR-focused companies, research institutions, and venture capital funding, particularly in London, Cambridge, and Oxford clusters.
Precision Medicine Investment :
Substantial government and private sector investment in precision medicine initiatives and genomic research programs is driving demand for CRISPR technologies across therapeutic and diagnostic applications.
UK CRISPR Market Dynamics
- The UK's post-Brexit regulatory independence has enabled faster innovation pathways and attracted international biotech investment. Key growth catalysts include rising healthcare expenditure on advanced therapeutics, expanding NHS coverage for gene-editing treatments, and the emergence of next-generation CRISPR platforms.
- The market will benefit from increased awareness among healthcare providers and patients, coupled with declining technology costs and improving efficacy data from ongoing clinical programs..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- The UK CRISPR market is valued at $160.7 million in 2025 and is projected to reach $284.7 million by 2030, growing at a 12.1% CAGR.
- The UK's advanced regulatory environment and NHS integration position it as a leader in CRISPR therapeutic adoption across Europe.
- Strong government funding through UKRI and NIHR, combined with world-class academic institutions, drives innovation and clinical trial leadership in the UK.
- The UK market is expected to see accelerated growth in rare genetic disorder treatments and oncology applications through 2030.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
UK CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
UK: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 25.6 | 26.8 | 29.9 | 33.5 | 37.4 | 41.8 | 46.8 | 52.4 | 11.9 |
| OTHER END USERS | 33.8 | 35.5 | 39.5 | 44.1 | 49.2 | 54.9 | 61.4 | 68.6 | 11.7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 36.2 | 38 | 42.4 | 47.6 | 53.4 | 59.9 | 67.3 | 75.6 | 12.2 |
| TOTAL | 95.6 | 100.3 | 111.8 | 125.2 | 140 | 156.6 | 175.5 | 196.6 | 12 |
UK: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 11.9 | 12.8 | 14.4 | 16.3 | 18.4 | 20.7 | 23.4 | 26.4 | 12.9 |
| OTHER END USERS | 12.7 | 13.8 | 15.3 | 17.1 | 19 | 21.2 | 23.6 | 26.3 | 11.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 15.7 | 17 | 19.2 | 21.7 | 24.5 | 27.6 | 31.2 | 35.3 | 13 |
| TOTAL | 40.4 | 43.7 | 48.9 | 55 | 61.8 | 69.5 | 78.2 | 88.1 | 12.5 |
Target Audience
- UK Biotech & Pharma Companies : CRISPR-focused firms and established pharmaceuticals need UK market intelligence to guide R&D investment, clinical trial planning, and commercialization strategies within their home market.
- Healthcare Investors & VCs : UK and international investors require detailed market data to evaluate funding opportunities, assess portfolio company growth potential, and identify emerging CRISPR startups in the British ecosystem.
- NHS & Healthcare Providers : Hospital trusts, clinical commissioning groups, and NHS England need market insights to plan budget allocation, evaluate CRISPR-based treatment adoption, and understand patient access pathways.
- Regulatory & Policy Bodies : MHRA, NICE, and UK government health agencies require market analysis to inform regulatory frameworks, reimbursement policies, and strategic healthcare innovation initiatives around CRISPR technologies.
- Academic & Research Institutions : UK universities and research centers need market data to guide grant applications, identify collaboration opportunities, and understand commercialization potential for CRISPR research programs.
Reasons to Buy this Report
- UK-Specific Market Sizing : Access precise valuation data and forecasts tailored exclusively to the UK market, enabling accurate budgeting and investment decisions for UK-focused CRISPR initiatives and partnerships.
- Regulatory & Compliance Insights : Understand the UK's unique regulatory landscape post-Brexit, including MHRA approval pathways, NHS reimbursement criteria, and compliance requirements specific to UK CRISPR commercialization.
- Competitive Landscape Analysis : Identify key UK-based CRISPR companies, research institutions, and clinical trial hubs to benchmark competitive positioning and identify partnership or acquisition opportunities within the British market.
- Growth Driver Identification : Discover UK-specific growth catalysts including government funding programs, NHS adoption trends, and regional biotech cluster dynamics that differentiate the UK market from broader European trends.
- Strategic Market Entry Planning : Develop informed market entry or expansion strategies for the UK with localized insights on investor sentiment, healthcare provider adoption rates, and patient demographics driving CRISPR demand.
Frequently asked questions
What is the current size of the UK CRISPR market in 2025?
The UK CRISPR market is valued at $160.7 million in 2025, representing a substantial segment of Europe's gene-editing market.
What is the projected size of the UK CRISPR market by 2030?
The UK CRISPR market is forecast to reach $284.7 million by 2030, reflecting strong growth momentum in the healthcare sector.
What is the growth rate of the UK CRISPR market?
The UK CRISPR market is expected to grow at a compound annual growth rate (CAGR) of 12.1% from 2025 to 2030.
What factors are driving growth in the UK CRISPR market?
Key drivers include the UK's robust regulatory framework, NHS integration of gene therapies, substantial government funding, and leadership in clinical trials for CRISPR-based therapeutics.
Which therapeutic areas are leading CRISPR adoption in the UK?
The UK market is seeing significant adoption in rare genetic disorders, oncology, and immunotherapy applications, supported by NHS coverage and clinical trial infrastructure.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
- Rest Of Europe CRISPR Market
- Rest Of Asia Pacific CRISPR Market
- Rest Of Latin America CRISPR Market
- US CRISPR Market
- Canada CRISPR Market
- Germany CRISPR Market
- France CRISPR Market
- Italy CRISPR Market
- Spain CRISPR Market
- China CRISPR Market
- Japan CRISPR Market
- India CRISPR Market
- Brazil CRISPR Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report